Is the EORTC QLQ-QNET21 Optimal for Patients with Neuroendocrine Tumors? Abstract #2122

Introduction: Quality of life (QoL) is important to all cancer patients. The EORTC QLQ-QNET21 is the most commonly used questionnaire in patients with neuroendocrine tumors (NETs).
Aim(s): This study aims to evaluate patients’ attitudes towards this questionnaire.
Materials and methods: A cross-sectional qualitative pilot study. Participants with NETs from Colombia, France, Netherlands and Russia completed the EORTC QLQ-QNET21 scale followed by a novel questionnaire to assess whether this questionnaire is optimal.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: MD Rachel van Leeuwaarde

To read results and conclusion, please login ...

Further abstracts you may be interested in

#452 Clinical and Psychometric Validation of the Disease-Specific Questionnaire Module (EORTC QLQ-GINET21) in Assessing Quality of Life of Patients with Neuroendocrine Tumors
Introduction: Quality of life (QoL) is an important outcome measure in clinical trials and is increasingly being used as an endpoint. The QLQ-GINET21 is a questionnaire developed with the EORTC QoL Group but which had not previously been validated.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr John Ramage
#1470 Exploring Gastrointestinal Symptoms And Their Impact on Quality of Life in Patients with Neuroendocrine Tumours
Introduction: Treatments in NETs have been studied for effects on tumour progression and carcinoid syndrome with minimal evidence on gastrointestinal(GI) symptom burden and impact on quality of life(QoL)
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Dr Mohid Khan
Authors: Williams M, Reid K, Ng S, Benny A, ...
#1676 NETTER-1 Phase III Trial: Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors
Introduction: Impairment in quality of life caused by tumor load and hormone-related symptoms is frequent in GEP-NET patients. In the Phase III NETTER-1 trial, patients with advanced, progressive midgut NETs were randomized to treatment with 177Lu-DOTATATE (177Lu; Lutathera®) or high-dose (60 mg) Octreotide LAR (Oct).
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Prof. Jonathan Strosberg
#2025 Health-Related Quality of Life Determinants in Swedish Patients after Surgery for Small Intestinal Neuroendocrine Tumors
Introduction: Overall survival for patients with small intestinal neuroendocrine tumors (siNETs) is often long even with metastatic disease, making quality of life issues especially relevant. The impact of surgery on their quality of life is unknown.
Conference: 15th Annual ENETS conference (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Anna Caterina Milanetto
#2146 Clinical Utility (CU) Evaluation of the Health-Related Quality-of-Life (HRQoL) QLQ-GINET21 Questionnaire (QNR) in the Treatment of Patients (pts) with Gastrointestinal (GI) Neuroendocrine Tumors (NETs). QUALINETS Study
Introduction: QLQ-GINET21 for pts with GI-NETs covers muscle/bone pain, body image, information, sexual function, symptoms, social function and disease-related concerns.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Guillermo de La Cruz
Authors: Gallego J, Reig O, Sastre J, Garcia I, ...